“…Novel study designs, such as cohort-embedded RCTs, should be encouraged and supported [52]. It would be imperative to use standardised criteria and validated thresholds in terms of patient eligibility, definitions of interventions, imaging modalities during treatment and monitoring, repeat treatments within a predefined timescale, biopsy schedules during follow-up, and outcome measures assessed at appropriate intervals and follow-up duration, since there is significant heterogeneity regarding FT [53,54]. The use of patient-reported outcome measures to measure functional and QoL outcomes should be encouraged.…”